US 12,186,329 B2
Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
Abigail Sloan Devlin, Cambridge, MA (US); Snehal N. Chaudhari, Cambridge, MA (US); Eric Garland Sheu, Brookline, MA (US); and David A. Harris, Arlington, MA (US)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US); and The Brigham and Women's Hospital, Inc., Boston, MA (US)
Appl. No. 17/270,201
Filed by President and Fellows of Harvard College, Cambridge, MA (US); and The Brigham and Women's Hospital, Inc., Boston, MA (US)
PCT Filed Aug. 23, 2019, PCT No. PCT/US2019/047856
§ 371(c)(1), (2) Date Feb. 22, 2021,
PCT Pub. No. WO2020/041673, PCT Pub. Date Feb. 27, 2020.
Claims priority of provisional application 62/722,010, filed on Aug. 23, 2018.
Prior Publication US 2021/0315908 A1, Oct. 14, 2021
Int. Cl. A61K 31/575 (2006.01); A61K 45/06 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 37/02 (2006.01)
CPC A61K 31/575 (2013.01) [A61K 45/06 (2013.01); A61P 3/00 (2018.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61P 37/02 (2018.01)] 20 Claims
 
1. A method for treating diabetes, the method comprising:
administering to a subject in need thereof an agent that increases the level of cholic acid-7-sulfate in the subject, wherein the agent is cholic acid-7-sulfate, or a pharmaceutically acceptable salt thereof.